Vivos Inc (RDGL)

$0.07 -0.01 (-9.38%)
Market Cap 32.96M
Revenue (ttm) 30,000.00
Net Income (ttm) -2.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,700.00%
Debt to Equity Ratio 0.00
Volume 1,140,100
Avg Vol 970,552
Day's Range N/A - N/A
Shares Out 454.67M
Stochastic %K 19%
Beta 1.04
Analysts Strong Buy
Price Target N/A

Company Profile

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. The company develops an yttrium-90 based precision radionuclide therapy device; RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing a universal laboratory cooling device; hydro...

Industry: Medical Devices
Sector: Healthcare
Phone: 509 222 2222
Address:
1030 N Center Parkway, Suite N288, Kennewick, United States
jhmlty
jhmlty Oct. 24 at 11:13 PM
$RDGL Lots of silence from the company. Did Imiss their monthly update?
1 · Reply
UWB67
UWB67 Oct. 24 at 7:46 PM
$RDGL Outside of seeking/pending regulatory approval to begin two separate human clinical trials towards marketing in the US and India, Vivos is focused on several initiatives like developing the ACTREC partnership. Also, Vivos likely added more contacts to their list of potential European strategic partnerships for BOTH RadioGel and IsoPet via the European Association of Nuclear Medicine conference that took place in early October 2025. In late 2019, Vivos revealed on X a Europe based contact that expressed a real eagerness to establish a strategic partnership with Vivos proposing Vivos use France as the gateway to the rest of Europe. The contact actually gave a speech praising IsoPet. -- Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession at any time is possible! GO VIVOS-US GO!! GO VIVOS-INDIA GO!! GO VIVOS-ISOPET GO!!
0 · Reply
Daybyday5
Daybyday5 Oct. 23 at 2:55 PM
$RDGL crickets on X….
0 · Reply
UWB67
UWB67 Oct. 22 at 1:41 PM
$RDGL The ONLY action that likely remains for Vivos to resubmit the IDE application is completing edits to the IDE application based on the respective feedback of the FDA and highly experienced regulatory consultant which could already be completed. Vivos did not anticipate any additional sprint discussions to move forward as of 21 August 2025. Finally, Vivos stated in its 22 August 2025 social media post on X: "IDE submission completed, FDA feedback provided, in process of addressing feedback. Regulatory Consultant Hired, with FDA experience, to help bolster our IDE submission." -- Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession is possible. GO VIVOS-US GO!! GO VIVOS-INDIA GO!! GO VIVOS-ISOPET GO!!
1 · Reply
Den44
Den44 Oct. 22 at 9:21 AM
$RDGL Locked and Loaded
0 · Reply
IPSO_FACTO
IPSO_FACTO Oct. 21 at 11:25 PM
$RDGL Ok, thank you for the advice Mr. know-it-all. Do you have anything more to add?
1 · Reply
UWB67
UWB67 Oct. 20 at 7:57 PM
$RDGL The FDA CONTINUES to review existing submissions despite the US government shutdown, according to the FY 2026 HHS Contingency Staffing Plan for Operations in the Absence of Enacted Annual Appropriations. Also, NO user fee is required for IDE application submissions, according to the FDA's Medical Device User Fees page. -- Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession is possible. GO VIVOS-US GO!! GO VIVOS-INDIA GO!! GO VIVOS-ISOPET GO!!
0 · Reply
UWB67
UWB67 Oct. 20 at 10:58 AM
$RDGL The FDA has NOT requested Vivos to provide data from DCGI approved clinical trials in India. Vivos India efforts will ALWAYS support Vivos US through the ENTIRE FDA process meaning until approval to market in the US. The FDA process in brief: bench testing, pre-clinical trials, submit application to begin clinical trials, clinical trials, submit application to market product. The following Vivos update is from Vivos' 29 September 2025 press release: "Based on feedback from the FDA, as part of our IDE application process, our formal protocol for the next phase of human trials in India will include immediate post treatment PET full- body scans to further validate RadioGel's safety profile". Said update is most likely on the Clinical Trial Protocol in general. -- Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession is possible and would be really nice. GO VIVOS-US GO!! GO VIVOS-INDIA GO!! GO VIVOS-ISOPET GO!!
1 · Reply
cbachand
cbachand Oct. 20 at 3:15 AM
$RDGL https://www.youtube.com/shorts/DsvsMN2buNg
0 · Reply
Shawna_Crawdfish
Shawna_Crawdfish Oct. 19 at 7:36 PM
$RDGL .1280 will be touched again as long as the ceo doesn’t mess with the AS&OS
2 · Reply
Latest News on RDGL
No data available.
jhmlty
jhmlty Oct. 24 at 11:13 PM
$RDGL Lots of silence from the company. Did Imiss their monthly update?
1 · Reply
UWB67
UWB67 Oct. 24 at 7:46 PM
$RDGL Outside of seeking/pending regulatory approval to begin two separate human clinical trials towards marketing in the US and India, Vivos is focused on several initiatives like developing the ACTREC partnership. Also, Vivos likely added more contacts to their list of potential European strategic partnerships for BOTH RadioGel and IsoPet via the European Association of Nuclear Medicine conference that took place in early October 2025. In late 2019, Vivos revealed on X a Europe based contact that expressed a real eagerness to establish a strategic partnership with Vivos proposing Vivos use France as the gateway to the rest of Europe. The contact actually gave a speech praising IsoPet. -- Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession at any time is possible! GO VIVOS-US GO!! GO VIVOS-INDIA GO!! GO VIVOS-ISOPET GO!!
0 · Reply
Daybyday5
Daybyday5 Oct. 23 at 2:55 PM
$RDGL crickets on X….
0 · Reply
UWB67
UWB67 Oct. 22 at 1:41 PM
$RDGL The ONLY action that likely remains for Vivos to resubmit the IDE application is completing edits to the IDE application based on the respective feedback of the FDA and highly experienced regulatory consultant which could already be completed. Vivos did not anticipate any additional sprint discussions to move forward as of 21 August 2025. Finally, Vivos stated in its 22 August 2025 social media post on X: "IDE submission completed, FDA feedback provided, in process of addressing feedback. Regulatory Consultant Hired, with FDA experience, to help bolster our IDE submission." -- Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession is possible. GO VIVOS-US GO!! GO VIVOS-INDIA GO!! GO VIVOS-ISOPET GO!!
1 · Reply
Den44
Den44 Oct. 22 at 9:21 AM
$RDGL Locked and Loaded
0 · Reply
IPSO_FACTO
IPSO_FACTO Oct. 21 at 11:25 PM
$RDGL Ok, thank you for the advice Mr. know-it-all. Do you have anything more to add?
1 · Reply
UWB67
UWB67 Oct. 20 at 7:57 PM
$RDGL The FDA CONTINUES to review existing submissions despite the US government shutdown, according to the FY 2026 HHS Contingency Staffing Plan for Operations in the Absence of Enacted Annual Appropriations. Also, NO user fee is required for IDE application submissions, according to the FDA's Medical Device User Fees page. -- Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession is possible. GO VIVOS-US GO!! GO VIVOS-INDIA GO!! GO VIVOS-ISOPET GO!!
0 · Reply
UWB67
UWB67 Oct. 20 at 10:58 AM
$RDGL The FDA has NOT requested Vivos to provide data from DCGI approved clinical trials in India. Vivos India efforts will ALWAYS support Vivos US through the ENTIRE FDA process meaning until approval to market in the US. The FDA process in brief: bench testing, pre-clinical trials, submit application to begin clinical trials, clinical trials, submit application to market product. The following Vivos update is from Vivos' 29 September 2025 press release: "Based on feedback from the FDA, as part of our IDE application process, our formal protocol for the next phase of human trials in India will include immediate post treatment PET full- body scans to further validate RadioGel's safety profile". Said update is most likely on the Clinical Trial Protocol in general. -- Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession is possible and would be really nice. GO VIVOS-US GO!! GO VIVOS-INDIA GO!! GO VIVOS-ISOPET GO!!
1 · Reply
cbachand
cbachand Oct. 20 at 3:15 AM
$RDGL https://www.youtube.com/shorts/DsvsMN2buNg
0 · Reply
Shawna_Crawdfish
Shawna_Crawdfish Oct. 19 at 7:36 PM
$RDGL .1280 will be touched again as long as the ceo doesn’t mess with the AS&OS
2 · Reply
UWB67
UWB67 Oct. 19 at 12:39 PM
$RDGL Two separate regulatory approvals (FDA-US and DCGI-India) in relatively quick succession is possible. GO VIVOS-US GO!! GO VIVOS-INDIA GO!! GO VIVOS-ISOPET GO!!
0 · Reply
SpotsPokerLife
SpotsPokerLife Oct. 17 at 10:04 PM
$AKAN $BYND $AZRH $BULL $RDGL all my honky ass cracker ass friends, and my black and brown brothers from other mothers should be loading $BYND before Monday morning. If you dont know, now you do. Squeeze pressure is in since its 80% short, news supposedly Monday that will out it over $1 (thats 30%) from here. I am personally going to hold until next friday to see how the options play out. You do you, but Monday is the 1st leg up.
1 · Reply
mc73307
mc73307 Oct. 16 at 11:19 PM
$RDGL anyone think this will be above 5 cents come the new year? I don't...
2 · Reply
jhmlty
jhmlty Oct. 15 at 2:16 PM
$RDGL 20 percent drop in 2 weeks. Ooofff!
1 · Reply
twighttrades1
twighttrades1 Oct. 15 at 1:33 AM
$RDGL - this jumk- the quickest refusal ever put. this on its ass… going to be a lot of tax loss’s pressure in dec- the trade is there… to double down if you believe then see how we play first half of 2026
2 · Reply
Daybyday5
Daybyday5 Oct. 14 at 12:54 PM
$RDGL .07 incoming whoa.
0 · Reply
Doccjc62
Doccjc62 Oct. 13 at 4:44 PM
$RDGL It’s possible that the company will announce the decision and not the resubmission of the IDE. We may be closer to that decision than we think .
2 · Reply
Fireballmillionaire
Fireballmillionaire Oct. 13 at 9:24 AM
$RDGL just a gut feeling here after watching other markets open, we might see a bit of a buying opportunity today or tomorrow.
2 · Reply
Doccjc62
Doccjc62 Oct. 11 at 5:52 AM
$RDGL Quiet here lately , unless Daybyday5 (Sasha on X)is still posting nonsense . Stock seems to be stuck in a trading range until the IDE is resubmitted . Company has been quiet , but that doesn’t mean things arent happening behind the scenes . For all we know, the IDE may have been resubmitted and we’re waiting for a decision . It happened with the BDD. (No announcement of resubmission). It’s comforting to know that the company has the help of an experienced FDA consultant to guide them through the IDE process .
1 · Reply
Daybyday5
Daybyday5 Oct. 9 at 2:18 PM
$RDGL No way .08 wasn't the bottom...
1 · Reply
Daybyday5
Daybyday5 Oct. 7 at 1:47 PM
$RDGL this is so dead even geriatrics on ihub cannot make it trending
1 · Reply
jhmlty
jhmlty Oct. 6 at 4:16 AM
$RDGL The move forward in India is good, but we are talking another 6 months to a year for the business set up and regulatory consent...in India. Then, maybe another shot at the submission.
1 · Reply